Protein Kinase Inhibitors: all 15,147 studies that test it

Page 36 of 152. Open to participants first (2,533), then studies with results posted, then the rest; newest registration first within each.

• A Study of INCB050465 in Participants With Autoimmune Hemolytic AnemiaCompletedNCT03538041Phase 2Results posted
• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibCompletedNCT03535740Phase 2Results posted
• Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for SurgeryTerminatedNCT03535506Phase 2Results posted
• Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial CarcinomaCompletedNCT03534804Phase 2Results posted
• Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSActive, not recruitingNCT03534323Phase 1/2Results posted
• Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)CompletedNCT03531957Phase 2Results posted
• Effect of a Proton Pump Inhibitor on the PK of TepotinibCompletedNCT03531762Phase 1Results posted
• Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy VolunteersCompletedNCT03530995Phase 1Results posted
• T-DM1 and Palbociclib for Metastatic HER2 Breast CancerCompletedNCT03530696Phase 2Results posted
• Lenvatinib and Eribulin in Advanced Soft Tissue SarcomaCompletedNCT03526679Phase 1/2Results posted
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 2Results posted
• Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.CompletedNCT03525834Phase 4Results posted
• Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed GlioblastomaCompletedNCT03522298Phase 2Results posted
• A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)Active, not recruitingNCT03521154Phase 3Results posted
• BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)CompletedNCT03520920Phase 2Results posted
• Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung CancerCompletedNCT03520842Phase 2Results posted
• Study of ASTX029 in Subjects With Advanced Solid TumorsCompletedNCT03520075Phase 1/2Results posted
• M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT03517969Phase 2Results posted
• Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])CompletedNCT03517449Phase 3Results posted
• Ibrutinib and PD-1 Blockade in High Risk Lymphocytic LeukemiaTerminatedNCT03514017Phase 2Results posted
• A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)CompletedNCT03512197Phase 3Results posted
• BGJ398 for the Treatment of Tumor-Induced OsteomalaciaTerminatedNCT03510455Phase 2Results posted
• Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom MacroglobulinemiaTerminatedNCT03506373Phase 2Results posted
• Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid CancerTerminatedNCT03506048Phase 2Results posted
• Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)CompletedNCT03502616Phase 3Results posted
• Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDTerminatedNCT03501979Phase 2Results posted
• Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain SyndromeTerminatedNCT03500159Phase 2Results posted
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
• A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical SolutionCompletedNCT03495817Phase 2Results posted
• Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous InvasionCompletedNCT03494816Phase 2Results posted
• Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran EtexilateCompletedNCT03492437Phase 1Results posted
• Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host DiseaseCompletedNCT03491215Phase 1/2Results posted
• Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic ArthritisCompletedNCT03486457Phase 3Results posted
• Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell LymphomaCompletedNCT03484819Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy ParticipantsCompletedNCT03482453Phase 1Results posted
• Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast CancerCompletedNCT03477396Phase 2Results posted
• Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib TrialsCompletedNCT03477175Phase 2Results posted
• Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal CancerCompletedNCT03475004Phase 2Results posted
• A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)CompletedNCT03474679Phase 3Results posted
• Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial CarcinomaCompletedNCT03473756Phase 1Results posted
• Phase 1A Safety Trial of Inhaled PK10571 (GB002)CompletedNCT03473236Phase 1Results posted
• A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)TerminatedNCT03472560Phase 2Results posted
• Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results posted
• A Study of ATI-50002 Topical Solution for the Treatment of VitiligoCompletedNCT03468855Phase 2Results posted
• Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationCompletedNCT03468478Phase 4Results posted
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerActive, not recruitingNCT03468218Phase 2Results posted
• (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Phase 3Results posted
• A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)CompletedNCT03463876Phase 2Results posted
• Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain MetastasesCompletedNCT03463525Phase 1Results posted
• Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed GlioblastomaCompletedNCT03463265Phase 2Results posted
• A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT03462719Phase 3Results posted
• Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric PatientsTerminatedNCT03458728Phase 1/2Results posted
• ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate CancerCompletedNCT03456804Phase 2Results posted
• Auranofin and Sirolimus in Treating Participants With Ovarian CancerTerminatedNCT03456700Phase 2Results posted
• A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerActive, not recruitingNCT03456076Phase 3Results posted
• G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung CancerCompletedNCT03455829Phase 1/2Results posted
• Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedNCT03449446Phase 2Results posted
• Palbociclib and Cetuximab in Metastatic Colorectal CancerCompletedNCT03446157Phase 2Results posted
• ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung CancerTerminatedNCT03445000Phase 2Results posted
• Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver CancerCompletedNCT03439891Phase 2Results posted
• Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal CancerCompletedNCT03439462Phase 1/2Results posted
• Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminatedNCT03439046Phase 3Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal MesotheliomaTerminatedNCT03436732Phase 1Results posted
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03435081Phase 3Results posted
• A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR MutationsCompletedNCT03434418Phase 2Results posted
• Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)TerminatedNCT03433703Phase 2Results posted
• Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before SurgeryActive, not recruitingNCT03433469Phase 2Results posted
• SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath TumorsCompletedNCT03433183Phase 2Results posted
• Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerCompletedNCT03428126Phase 2Results posted
• A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically AdvisableCompletedNCT03428100Phase 3Results posted
• Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.CompletedNCT03427866Phase 2Results posted
• Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung CancerTerminatedNCT03425006Phase 2Results posted
• A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid TumorsCompletedNCT03420742Phase 1Results posted
• A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaCompletedNCT03418922Phase 1Results posted
• SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard TherapyCompletedNCT03417895Phase 2Results posted
• Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionCompletedNCT03417778Phase 1Results posted
• A Phase II Study of BVD-523 in Metastatic Uveal MelanomaTerminatedNCT03417739Phase 2Results posted
• Osimertinib for NSCLC With EGFR Exon 20 Insertion MutationCompletedNCT03414814Phase 2Results posted
• A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian CancerCompletedNCT03414047Phase 2Results posted
• Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03414034Phase 2Results posted
• Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT03410693Phase 2/3Results posted
• Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03410108Phase 2Results posted
• An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusTerminatedNCT03407482Phase 2Results posted
• Regorafenib and Nivolumab Simultaneous Combination TherapyCompletedNCT03406871Phase 1Results posted
• Red Blood Cell ATP Release and Vascular Function in HumansCompletedNCT03404843Phase 2Results posted
• Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's DiseaseCompletedNCT03402659Phase 2Results posted
• VAY736 in Combination With Ibrutinib in Patients With CLL on IbrutinibTerminatedNCT03400176Phase 1Results posted
• A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of NemiralisibCompletedNCT03398421Phase 1Results posted
• Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT03395340Phase 2Results posted
• A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)CompletedNCT03395210Phase 2Results posted
• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's DiseaseCompletedNCT03395184Phase 2Results posted
• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsActive, not recruitingNCT03390504Phase 3Results posted
• Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain TumorsCompletedNCT03387020Phase 1Results posted
• Survival Prolongation by Rationale Innovative GenomicsTerminatedNCT03386929Phase 1/2Results posted
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE ScoreCompletedNCT03386539Phase 3Results posted
• Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.CompletedNCT03379727Phase 3Results posted
• An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCompletedNCT03377361Phase 1/2Results posted
• Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerActive, not recruitingNCT03377023Phase 1/2Results posted
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsActive, not recruitingNCT03375320Phase 3Results posted
• Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)CompletedNCT03374254Phase 1Results posted

← Protein Kinase Inhibitors overview